Jeff Martin
Stock Analyst at Roth Capital
(4.38)
# 367
Out of 5,124 analysts
65
Total ratings
60.66%
Success rate
16.3%
Average return
Main Sectors:
Stocks Rated by Jeff Martin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BWMN Bowman Consulting Group | Maintains: Buy | $45 → $50 | $32.97 | +51.65% | 6 | Dec 9, 2025 | |
| OSIS OSI Systems | Maintains: Buy | $280 → $292 | $255.06 | +14.48% | 17 | Dec 1, 2025 | |
| PERI Perion Network | Reiterates: Buy | $14 → $15 | $9.58 | +51.36% | 10 | Nov 13, 2025 | |
| NSP Insperity | Maintains: Buy | $85 → $74 | $38.72 | +91.12% | 9 | Aug 4, 2025 | |
| FC Franklin Covey Co. | Maintains: Buy | $30 → $27 | $16.78 | +60.91% | 8 | Jul 7, 2025 | |
| TACT TransAct Technologies | Maintains: Buy | $6 → $5 | $4.00 | +25.00% | 1 | May 14, 2025 | |
| BGSF BGSF, Inc. | Maintains: Buy | $12 → $9 | $4.63 | +94.38% | 1 | Mar 20, 2025 | |
| BBSI Barrett Business Services | Maintains: Buy | $43 → $45 | $36.21 | +24.28% | 5 | Nov 7, 2024 | |
| HCKT The Hackett Group | Maintains: Buy | $29 → $30 | $19.63 | +52.83% | 6 | Nov 5, 2024 | |
| GLMD Galmed Pharmaceuticals | Initiates: Buy | $5,760 | $0.75 | +767,388.34% | 2 | Nov 15, 2017 |
Bowman Consulting Group
Dec 9, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $32.97
Upside: +51.65%
OSI Systems
Dec 1, 2025
Maintains: Buy
Price Target: $280 → $292
Current: $255.06
Upside: +14.48%
Perion Network
Nov 13, 2025
Reiterates: Buy
Price Target: $14 → $15
Current: $9.58
Upside: +51.36%
Insperity
Aug 4, 2025
Maintains: Buy
Price Target: $85 → $74
Current: $38.72
Upside: +91.12%
Franklin Covey Co.
Jul 7, 2025
Maintains: Buy
Price Target: $30 → $27
Current: $16.78
Upside: +60.91%
TransAct Technologies
May 14, 2025
Maintains: Buy
Price Target: $6 → $5
Current: $4.00
Upside: +25.00%
BGSF, Inc.
Mar 20, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $4.63
Upside: +94.38%
Barrett Business Services
Nov 7, 2024
Maintains: Buy
Price Target: $43 → $45
Current: $36.21
Upside: +24.28%
The Hackett Group
Nov 5, 2024
Maintains: Buy
Price Target: $29 → $30
Current: $19.63
Upside: +52.83%
Galmed Pharmaceuticals
Nov 15, 2017
Initiates: Buy
Price Target: $5,760
Current: $0.75
Upside: +767,388.34%